Regulus Therapeutics Inc.
RGLS
$7.86
-$0.01-0.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 55.16% | 58.25% | 140.41% | 76.54% | 61.99% |
| Gross Profit | -55.16% | -58.25% | -140.41% | -76.54% | -61.99% |
| SG&A Expenses | 51.54% | 47.37% | 36.29% | 28.70% | 9.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.92% | 60.86% | 49.95% | 28.55% | 12.15% |
| Operating Income | -58.92% | -60.86% | -49.95% | -28.55% | -12.15% |
| Income Before Tax | -51.51% | -54.34% | -44.69% | -24.19% | -9.13% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Earnings from Continuing Operations | -51.51% | -54.34% | -44.69% | -24.18% | -9.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.51% | -54.34% | -44.69% | -24.18% | -9.13% |
| EBIT | -58.92% | -60.86% | -49.95% | -28.55% | -12.15% |
| EBITDA | -59.11% | -60.92% | -49.74% | -28.22% | -11.80% |
| EPS Basic | 50.17% | 44.85% | 32.25% | 25.65% | 20.21% |
| Normalized Basic EPS | 50.17% | 44.85% | 32.26% | 25.66% | 20.22% |
| EPS Diluted | 50.17% | 44.85% | 32.41% | 25.81% | 20.37% |
| Normalized Diluted EPS | 50.17% | 44.85% | 32.26% | 25.66% | 20.22% |
| Average Basic Shares Outstanding | 198.30% | 195.77% | 147.06% | 96.39% | 38.62% |
| Average Diluted Shares Outstanding | 198.30% | 195.77% | 147.06% | 96.39% | 38.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |